Amgen Sunday strategy focus, stock and pipeline under long-term scrutiny

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 14:07.

Amgen Inc. (US0311621009) remains a core large-cap name in global biotechnology. The company is listed on NASDAQ, features in major indices such as the S&P 500 and NASDAQ-100, and draws long-term investors thanks to its established portfolio of biologic therapies.

How Amgen earns its revenue

Amgen generates most of its revenue from innovative biologic medicines in oncology, hematology, cardiovascular disease, and inflammation, complemented by biosimilars and emerging gene-based approaches.

The company has grown through a mix of internal R&D and acquisitions over multiple decades, including deals such as its purchase of Horizon Therapeutics to broaden its rare disease franchise, as documented in its investor relations materials and recent filings.

Long-term strategy and pipeline focus

Amgen’s long-term strategy centers on expanding its pipeline in oncology and immunology, scaling its biosimilars business, and maintaining disciplined capital allocation through dividends and share repurchases, according to investor presentations and annual reports.

The group consistently highlights a focus on first-in-class and best-in-class biologics, supported by large-scale manufacturing capabilities and global commercial reach; these factors underpin its positioning against peers like Pfizer, Merck, and Bristol Myers Squibb in the broader biopharma sector.

Representative Amgen product portfolio

Amgen’s marketed products include flagship brands such as Enbrel for inflammatory conditions, Prolia and Xgeva for bone health, and Repatha for lowering LDL cholesterol, as detailed on the company’s product pages and regulatory documents.

In addition, Amgen has biosimilars like Amgevita and Equidate in Europe and other markets, positioning it in the growing segment of lower-cost alternatives to originator biologics, according to its corporate and investor materials.

Where Amgen stock trades today

Amgen stock trades on NASDAQ under the ticker AMGN; the latest price, in US dollars, is quoted during US market hours on NASDAQ’s data pages and major financial portals.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.